Open Access
Ferroptosis: A novel therapeutic target of natural products against doxorubicin-induced cardiotoxicity
2
Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China. Electronic address: shuqi@zjcc.org.cn.
3
Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China. Electronic address: zhujf@zjcc.org.cn.
Тип публикации: Journal Article
Дата публикации: 2024-09-01
scimago Q1
wos Q1
БС1
SJR: 1.775
CiteScore: 12.8
Impact factor: 7.5
ISSN: 07533322, 19506007
PubMed ID:
39079260
Краткое описание
Doxorubicin (DOX), a commonly used chemotherapy drug, is hindered due to its tendency to induce cardiotoxicity (DIC). Ferroptosis, a novel mode of programmed cell death, has received substantial attention for its involvement in DIC. Recently, natural product-derived ferroptosis regulator emerged as a potential strategy for treating DIC. In this review, a comprehensive search was conducted across PubMed, Web of Science, Google Scholar, and ScienceDirect databases to gather relevant articles on the use of natural products for treating DIC in relation to ferroptosis. The available papers were carefully reviewed to summarize the therapeutic effects and underlying mechanisms of natural products in modulating ferroptosis for DIC treatment. It was found that ferroptosis plays an important role in DIC pathogenesis, with dysregulated expression of ferroptosis-related proteins strongly implicated in the condition. Natural products, such as flavonoids, polyphenols, terpenoids, and quinones can act as GPX4 activators, Nrf2 agonists, and lipid peroxidation inhibitors, thereby enhancing cell viability, attenuating myocardial fibrosis, improving cardiac function, and suppressing ferroptosis in both in vitro and in vivo models of DIC. This review demonstrates a strong correlation between DOX-induced cardiac ferroptosis and key proteins, such as GPX4, Keap1, Nrf2, AMPK, and HMOX1. Natural products are likely to exert therapeutic effects against DIC by modulating the activity of these proteins.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Топ-30
Журналы
|
1
2
3
|
|
|
Frontiers in Pharmacology
3 публикации, 13.04%
|
|
|
European Journal of Medicinal Chemistry
2 публикации, 8.7%
|
|
|
Drug Design, Development and Therapy
2 публикации, 8.7%
|
|
|
Nutrients
1 публикация, 4.35%
|
|
|
Journal of Cellular and Molecular Medicine
1 публикация, 4.35%
|
|
|
ACS Biomaterials Science and Engineering
1 публикация, 4.35%
|
|
|
Heart and Mind
1 публикация, 4.35%
|
|
|
Biomolecules
1 публикация, 4.35%
|
|
|
Biochemical and Biophysical Research Communications
1 публикация, 4.35%
|
|
|
Journal of Pharmaceutical and Biomedical Analysis
1 публикация, 4.35%
|
|
|
Marine Drugs
1 публикация, 4.35%
|
|
|
Journal of Ethnopharmacology
1 публикация, 4.35%
|
|
|
Pharmacognosy Magazine
1 публикация, 4.35%
|
|
|
International Journal of Molecular Sciences
1 публикация, 4.35%
|
|
|
Molecular Biotechnology
1 публикация, 4.35%
|
|
|
Acta Medica Bulgarica
1 публикация, 4.35%
|
|
|
International Journal of Molecular Medicine
1 публикация, 4.35%
|
|
|
Molecules
1 публикация, 4.35%
|
|
|
FASEB Journal
1 публикация, 4.35%
|
|
|
1
2
3
|
Издатели
|
1
2
3
4
5
|
|
|
Elsevier
5 публикаций, 21.74%
|
|
|
MDPI
5 публикаций, 21.74%
|
|
|
Frontiers Media S.A.
3 публикации, 13.04%
|
|
|
Taylor & Francis
2 публикации, 8.7%
|
|
|
Wiley
1 публикация, 4.35%
|
|
|
American Chemical Society (ACS)
1 публикация, 4.35%
|
|
|
SAGE
1 публикация, 4.35%
|
|
|
Springer Nature
1 публикация, 4.35%
|
|
|
Walter de Gruyter
1 публикация, 4.35%
|
|
|
Spandidos Publications
1 публикация, 4.35%
|
|
|
Federation of American Societies for Experimental Biology (FASEB)
1 публикация, 4.35%
|
|
|
1
2
3
4
5
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
23
Всего цитирований:
23
Цитирований c 2024:
23
(100%)
Цитировать
ГОСТ |
RIS |
BibTex
Цитировать
ГОСТ
Скопировать
Yi X. et al. Ferroptosis: A novel therapeutic target of natural products against doxorubicin-induced cardiotoxicity // Biomedicine and Pharmacotherapy. 2024. Vol. 178. p. 117217.
ГОСТ со всеми авторами (до 50)
Скопировать
Yi X., Wang Q., Zhang M., Zhang Z., Shu Q., Zhu J. Ferroptosis: A novel therapeutic target of natural products against doxorubicin-induced cardiotoxicity // Biomedicine and Pharmacotherapy. 2024. Vol. 178. p. 117217.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1016/j.biopha.2024.117217
UR - https://linkinghub.elsevier.com/retrieve/pii/S0753332224011016
TI - Ferroptosis: A novel therapeutic target of natural products against doxorubicin-induced cardiotoxicity
T2 - Biomedicine and Pharmacotherapy
AU - Yi, Xiaojiao
AU - Wang, Qi
AU - Zhang, Mengjie
AU - Zhang, Zhijun
AU - Shu, Qi
AU - Zhu, Junfeng
PY - 2024
DA - 2024/09/01
PB - Elsevier
SP - 117217
VL - 178
PMID - 39079260
SN - 0753-3322
SN - 1950-6007
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2024_Yi,
author = {Xiaojiao Yi and Qi Wang and Mengjie Zhang and Zhijun Zhang and Qi Shu and Junfeng Zhu},
title = {Ferroptosis: A novel therapeutic target of natural products against doxorubicin-induced cardiotoxicity},
journal = {Biomedicine and Pharmacotherapy},
year = {2024},
volume = {178},
publisher = {Elsevier},
month = {sep},
url = {https://linkinghub.elsevier.com/retrieve/pii/S0753332224011016},
pages = {117217},
doi = {10.1016/j.biopha.2024.117217}
}